Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
duvortuxizumab
- Development stage
- Discontinued
- Lead developer
- Johnson & Johnson
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Duvortuxizumab (MGD011) is a bispecific Dual-Affinity Re-Targeting (DART) molecule designed to simultaneously target CD19 and CD3. Developed by MacroGenics in collaboration with Janssen Biotech, the therapeutic was engineered to redirect T cells to eliminate malignant B cells expressing CD19. It was primarily investigated for the treatment of various B-cell hematological malignancies, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and chronic lymphocytic leukemia (CLL). In December 2014, Janssen licensed the global rights to the molecule for a $50 million upfront payment and a $75 million equity investment. However, Janssen terminated the agreement in August 2017 following safety concerns, specifically treatment-related neurotoxicity observed during Phase 1 dose-escalation trials. MacroGenics regained worldwide rights to the asset in 2018, but the program has since been deprioritized.
- Other names
- CD19 x CD3 DART moleculeCD-19 x CD3 DART moleculeCD 19 x CD3 DART moleculeJNJ-64052059JNJ64052059JNJ 64052059
02
Targets
CD19 (B lymphocyte antigen CD19)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on duvortuxizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on duvortuxizumab.